open access

Vol 50, No 3 (2012)
Original paper
Submitted: 2012-10-08
Accepted: 2012-10-08
Published online: 2012-10-08
Get Citation

Antitumor effect of murine dendritic and tumor cells transduced with IL-2 gene

Justyna Wojas-Turek, Elżbieta Pajtasz-Piasecka, Joanna Rossowska, Egbert Piasecki, Danuta Duś
DOI: 10.5603/FHC.2012.0056
·
Folia Histochem Cytobiol 2012;50(3):414-419.

open access

Vol 50, No 3 (2012)
ORIGINAL PAPERS
Submitted: 2012-10-08
Accepted: 2012-10-08
Published online: 2012-10-08

Abstract

Interleukin (IL-) 2 acts on a number of types of immune cells promoting their effector functions. To replace
systemic administration of recombinant form of this cytokine, various genetically modified cells have been used in
different preclinical models for tumor growth inhibition. In this study, dendritic or tumor cells transduced with retroviral
vector carrying IL-2 gene (JAWS II/IL-2, X63/IL-2, MC38/IL-2 cells) alone or combined with tumor antigenstimulated
dendritic cells (JAWS II/TAg) were exploited to treat colon carcinoma MC38-bearing mice. After the
peritumoral injection of vaccine cells, the tumor growth delay and the increase in the number of tumor infiltrating
CD4+ and CD8+ T lymphocytes were noted. A considerable increase in CD4+ cell influx into tumor tissue was observed
when JAWS II/IL-2 cells or JAWS II/TAg with syngeneic MC38/IL-2 cells were applied. The increase in
intensity of CD8+ cell infiltration was associated with immune reaction triggered by the same combination of applied
cells or JAWS II/TAg with allogeneic X63/IL-2 cells. The effect observed in vivo was accompanied by MC38/0 cell
specific cytotoxic activity of spleen cells in vitro. Thus, the application of vaccines, including IL-2-secreting cells of
various origins, was able to induce different antitumor responses polarized by exogenous IL-2 and the encountered
tumor antigen.

Abstract

Interleukin (IL-) 2 acts on a number of types of immune cells promoting their effector functions. To replace
systemic administration of recombinant form of this cytokine, various genetically modified cells have been used in
different preclinical models for tumor growth inhibition. In this study, dendritic or tumor cells transduced with retroviral
vector carrying IL-2 gene (JAWS II/IL-2, X63/IL-2, MC38/IL-2 cells) alone or combined with tumor antigenstimulated
dendritic cells (JAWS II/TAg) were exploited to treat colon carcinoma MC38-bearing mice. After the
peritumoral injection of vaccine cells, the tumor growth delay and the increase in the number of tumor infiltrating
CD4+ and CD8+ T lymphocytes were noted. A considerable increase in CD4+ cell influx into tumor tissue was observed
when JAWS II/IL-2 cells or JAWS II/TAg with syngeneic MC38/IL-2 cells were applied. The increase in
intensity of CD8+ cell infiltration was associated with immune reaction triggered by the same combination of applied
cells or JAWS II/TAg with allogeneic X63/IL-2 cells. The effect observed in vivo was accompanied by MC38/0 cell
specific cytotoxic activity of spleen cells in vitro. Thus, the application of vaccines, including IL-2-secreting cells of
various origins, was able to induce different antitumor responses polarized by exogenous IL-2 and the encountered
tumor antigen.
Get Citation
About this article
Title

Antitumor effect of murine dendritic and tumor cells transduced with IL-2 gene

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 50, No 3 (2012)

Article type

Original paper

Pages

414-419

Published online

2012-10-08

DOI

10.5603/FHC.2012.0056

Bibliographic record

Folia Histochem Cytobiol 2012;50(3):414-419.

Authors

Justyna Wojas-Turek
Elżbieta Pajtasz-Piasecka
Joanna Rossowska
Egbert Piasecki
Danuta Duś

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl